K-V Pharma to relaunch product, shares soar. Revolutions Medical nabs DOD contract. After the bell: Aria to provide update Print
By BioMedReports.com Staff   
Friday, 10 September 2010 18:25

Below is a list of the companies that made news in the healthcare sector on Friday, September 10, 2010.


After the bell Friday, shares of ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) jumped more than 5% after the company announced that it will hold an investor conference call at 9:00 a.m. (ET) on Monday, September 13, 2010 to provide an update on the clinical development of its investigational pan-BCR-ABL inhibitor, AP24534. Harvey J. Berger, M.D., chairman and chief executive officer, will host the call along with other members of the ARIAD management team. The Company will announce the highlights in a press release to be issued before the market opens on September 13, 2010 prior to the conference call.

NexMed, Inc. (Nasdaq:NEXM), after the market close today announced the results of its Special Meeting of Stockholders, held today, Friday, September 10, 2010.

At the Special Meeting, the Stockholders of the Company approved, by an affirmative majority vote, to change the name of the Company from NexMed, Inc. to Apricus Biosciences, Inc. ("Apricus Bio"), effective September 10, 2010. The name change was brought on to reflect the broader focus of the Company’s development programs. The Company’s common stock will commence trading under the symbol, NASDAQ: APRI, effective at the open of the market on Tuesday, September 14, 2010.

Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its management will host a conference call and webcast on Monday, September 13, 2010, at 5:30 a.m. Pacific Time (PT) / 8:30 a.m. Eastern Time (ET) to discuss top-line results from its lintuzumab (SGN-33) phase IIb clinical trial in acute myeloid leukemia (AML).

In news from earlier in the day:

K-V Pharmaceutical Company (NYSE: KVa/KVb) announced today that it has received notice from the U.S. Food and Drug Administration of the successful completion of an inspection of the Company's facilities and approval to return its first product to market. Under the Company's Consent Decree, successful FDA inspections of the Company's quality systems, processes and facilities are expected to be required before K-V is permitted to resume manufacturing and shipment of particular products. During the week of August 16, 2010, the FDA undertook an inspection of the Company's quality systems, manufacturing processes and facilities focusing on the first product dosage form for reintroduction by the Company into the marketplace. The inspection was successfully completed.

The Company received notification from the FDA on September 8, 2010 of approval to ship into the marketplace the first product approved under the consent decree, i.e. Potassium Chloride. The Company expects that initial shipments of its Micro-K®10mEq and Micro-K® 8mEq will begin the week of September 13, 2010. The FDA is expected to conduct additional inspections with respect to other Company products before deciding whether other products may be manufactured and marketed.

Greg Divis, President of Ther-Rx Corporation and Interim President and Chief Executive Officer of K-V Pharmaceutical Company, stated, "Today marks a significant milestone in our efforts to restore business operations at K-V. The successful FDA inspection of our facilities and approval of our return to market demonstrates our hard work and commitment to meeting and sustaining current Good Manufacturing Practices requirements. We are committed to continuing to move K-V through further successful inspections and to obtain additional product approvals from the FDA."

Shares of K-V nearly doubled on the day, jumping $1.25 or nearly 75% higher to close at $2.94.

Revolutions Medical Corporation (OTCBB:RMCP) to receive contract with the United States Department of Defense HIV/AIDS Prevention Program (DHAPP) for multiple countries for its proprietary 3cc RevVac Safety Syringe.

Revolutions Medical is a safety medical device and software application company. Its products include the RevVac safety syringe (FDA approved), safety blood drawing device and safety IV catheter. The Company also provides RevColor, RevDisplay and Rev3D -- software solutions and proprietary tools that are compatible with standard MRIs and standard PACS. The software suite's functionality includes sorting of images, color, 3D and automatic segmentation of images.

On nearly 10 times the daily average volume, shares of Revolutions soared more than 31% or 30 cents to close the day at $1.275.

China-Biotics, Inc. (Nasdaq:CHBT) a leading developer, manufacturer and distributor of probiotics products in China, today confirms that there has been an organized effort to distribute false rumors regarding the Company by emails, phone calls and websites. The Company suspects this is motivated by short selling interest in the Company's stock. These messages are false and damage China-Biotics' corporate image and its management's credibility. The Company has acted in a legal and ethical manner and it has not provided false disclosures of the Company's operations or financial data to investors or the United States securities authorities. China-Biotics is working with its legal counsel and the relevant authorities on further action against those responsible.

The Medicines Company (NASDAQ:MDCO) announced today that the U.S. District Court for the Eastern District of Virginia denied APP Pharmaceuticals, LLC's motion to intervene for the purpose of appeal in a case between The Medicines Company and the U.S. Patent and Trademark Office (PTO), the U.S. Food and Drug Administration and the U.S. Department of Health and Human Services.

The Court ruled on August 3 ordering the U.S. Patent and Trademark Office (PTO) to consider The Medicines Company's Angiomax® (bivalirudin) patent term extension application timely filed. The lawsuit challenged the PTO's denial of the application for an extension of the term of U.S. Patent No. 5,196,404, the principal U.S. patent that covers Angiomax.

Also Friday:

Advanced Cell Technology, Inc.(OTCBB:ACTC) announced today that the company will present at the Rodman & Renshaw 12th Annual Global Investment onference at the New York Palace Hotel in New York City.

ArQule, Inc. (Nasdaq: ARQL) today announced that the Company will present at the 2010 Stifel Nicolaus Healthcare Conference on September 17, 2010 at 11:30 a.m. and at the UBS Global Life Sciences Conference on September 20, 2010 at 12:30 p.m.

Bohai Pharmaceuticals Group, Inc. (OTCBB/OTCQB: BOPH), a China-based pharmaceutical company engaged in the production, manufacturing and distribution of Traditiona Chinese Medicine (TCM) in China, today announced revenue and earnings guidance for its fiscal year ending June 30, 2010.

Bristol-Myers Squibb Company (NYSE: BMY) is commencing today, through its wholly owned subsidiary Zeus Acquisition Corporation, a cash tender offer to purchase all out tanding shares of common stock of ZymoGenetics, Inc. (NASDAQ: ZGEN). Bristol-Myers Squibb announced on Tuesday, September 7, 2010 its intent to acquire ZymoGenetics.

Cardiac Network, Inc. (PINKSHEETS:CNWI), a developer of advanced mobile medical monitoring systems, announced today the appointment of Anthony P. Bonito to fill a vacant seat on Cardiac Network's Board of Directors.

China Cord Blood Corporation (NYSE:CO) China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing, and stem cell storage services, today announced unaudited financial results for the first fiscal quarter ended June 30, 2010.

China Jo-Jo Drugstores, Inc. (NASDAQ:CJJD) which operates a retail pharmacy chain in Zhejiang Province, today announced that the Company will present at the Rodman & Renshaw Annual Global Investment Conference at The Palace Hotel in New York City on Monday September 13, 2010 at 3:15pm Eastern time.

Cortex Pharmaceuticals, Inc. (OTCBB: CORX) President and CEO, Mark A. Varney, Ph.D., will present at Rodman & Renshaw's 12th Annual Healthcare Conference at 3:40 PM (EDT) on Monday, September 13, 2010 in the Fahnestock Salon at the New York Palace Hotel in New York City.

Covance Inc. (NYSE:CVD) today announced that it will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 14, 2010 at 2:10 p.m. ET.

Covidien (NYSE:COV), a leading global provider of healthcare products, today announced it supports the U.S. Food and Drug Administration's (FDA) labeling changes for gadolinium-based contrast agents for patients with acute kidney injury or chronic, severe kidney disease.

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that 47 presentations at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston from September 12-15 will cover recent research related to its marketed antibiotic, CUBICIN® (daptomycin for injection), as well as the company's clinical and preclinical antibiotic programs.

CytoGenix, Inc. (Pink sheets: CYGX) announced today that it has expanded its Advisory Board.

Deltagen, Inc. (Pink Sheets:DGEN), a leading provider of drug discovery tools to the biopharmaceutical industry, today reported unaudited consolidated financia results for the three months ended June 30, 2010.

Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, today announced the resignation of its Chief Financial Officer, Mario Crovetto, effective January 2011.

GeckoSystems Intl. Corp. (PINKSHEETS: GCKO) announced today that they have enhanced the benefit of owning one of their personal companion, telepresence capable mobile robots with improvements in several of their proprietary technologies as a result of their groundbreaking in home elder care robot trials begun late last fall.

Healthmed Services, Ltd. (OTCQB:HEME), an innovative software development company, is pleased to announce the Company has added two new executives to move the Company forward in developing and offering its products. Healthmed welcomes Mr. William Morland as the Company's Chief Executive Officer and Mr. Dale Paisley as Healthmed's Chief Financial Officer.

Human Genome Sciences, Inc. (NASDAQ: HGSI) announced today that its presentation at the 2010 Morgan Stanley Global Healthcare Unplugged Conference will be webcast and may be accessed at www.hgsi.com.

Inovio Pharmaceuticals, Inc. (NYSE Amex:INO), a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announce today that it will host a conference call on Monday, September 13, 2010, at 8:30 a.m. Eastern Time to update investors on clinical trial results and plans for further studies.

MMRGlobal (OTCBB: MMRF) Chairman and CEO Robert H. Lorsch, in a blog to shareholders today, said: As we end the summer the healthcare revolution is in full swing -- Personal Health Records are just in the public consciousness.

Orexigen® Therapeutics, Inc. (Nasdaq:OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the Rodman & Renshaw Annual Global Investment Conference.

Orthofix International N.V., (NASDAQ:OFIX) announced today that it will participate in the Stifel Nicolaus 2010 Healthcare Conference in Boston.

Orthovita, Inc. (NASDAQ:VITA), an orthobiologics and biosurgery company, announced today that it will present at the UBS Global Life Sciences Conference in New York Nancy Broadbent, Senior Vice President and Chief Financial Officer of Orthovita, is scheduled to present on Monday, September 20, 2010, at 3:30 p.m. Eastern Time, at the Grand Hyatt New York Hotel, 109 East 42nd Street at Grand Central Terminal, New York, NY 10017.

Palatin Technologies, Inc. (NYSE Amex:PTN) announced that it will be presenting at the Rodman & Renshaw Annual Global Investment Conference / 12th Annual Healthcare Conference on Tuesday, September 14, 2010 at 10:50 AM ET.

Paradigm Medical Industries, Inc. (PINKSHEETS: PDMI) announced today that it had completed the planned upgrades and improvements to its popular Dicon LD 400 Perimeter.

PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, today announced that the Company will present at the Stifel Nicolaus Healthcare Conference on Friday, September 17 at 10:55 am Eastern Time at the Four Seasons Hotel in Boston.

PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy and hospital pharmacy management services, today announced that Michael J. Culotta, Executive Vice President and Chief Financial Officer, will make a presentation regarding the Company at the Credit Suisse 1st Annual Small & Mid Cap Conference 2010 in Boston on Wednesday, September 15, 2010, at 1:50 p.m. Eastern Time.

Power3 Medical Products, Inc. (OTCBB: PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced today that it delivered four poster presentations at the 2010 International Conference on Alzheimer's Disease (ICAD) in Honolulu, Hawaii.

Pro-Pharmaceuticals, Inc. (OTC: PRWP), a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today announced that Company execut ves are scheduled to present a corporate update at Rodman and Renshaw's Annual Global Investment Conference on Monday, September 13, 2010 at 4:30 pm EDT at The New York Palace Hotel in New York City.

SciMeDent Health, Corp. f/k/a Trend Exploration, Inc. (PINKSHEETS: TRDX) today confirms it has completed the structuring of DiabetRX Pharma Corp. ("DiabetRX") which will be assigned the Sublicense and upon Final Closing will be 100% owned by TRDX.

Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its management will host a conference call and webcast on Monday, September 13, 2010, at 5:30 a.m. Pacific Time (PT) / 8:30 a.m. Eastern Time (ET) to discuss top-line results from its lintuzumab (SGN-33) phase IIb clinical trial in acute myeloid leukemia (AML).

Stellar Biotechnologies, Inc. (PINKSHEETS: SBOTF) (TSX-V: KLH) announces filing for patent protection of inventions related to its native Immunogenic (IMG) KLH technology platform and immune status monitoring product portfolio.KLH (keyhole limpet hemocyanin) is presently the most pharmaceutically important ICP (immune carrier protein) and IMG KLH is the most effective immune stimulant for use in cancer, viral and parasite vaccines; animal vaccines; and diagnostic products.

Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN), one of the top global providers of high quality stevia extracts including Rebaudioside A 98, today announced that the Company will present at the Rodman & Renshaw Annual Global Investment Conference on Tuesday, September14th, 2010.

Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) will host a live audio webcast at the Morgan Stanley Global Healthcare Conference with Eyal Desheh, Chief Financial Officer, Teva Pharmaceutical Industries Ltd., presenting on Tuesday, September 14, 2010 in New York City.

TomoTherapy Incorporated (NASDAQ :TOMO), maker of advanced radiation therapy solutions for cancer care, today announced that CFO Thomas Powell and Vice President of Operations and Business Development Eric Schloesser will present at Baird's 2010 Health Care Conference on Wednesday, September 15, 2010 at 11:00 a.m. ET.

Zalicus Inc. (NASDAQ: ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that Mark Corrigan, President and CEO is scheduled to present at the Rodman and Renshaw Annual Global Healthcare Conference at 4:30pm EDT on September 14, 2010, at the New York Palace Hotel.

Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus